# Tirzepatide (Zepbound, Mounjaro) Slashes Diabetes Risk by 94 Percent for Certain People at High Risk – Tirzepatide demonstrates a remarkable reduction in diabetes risk by 94% for high-risk individuals, according to a recent study. – The study, published in The New England Journal of Medicine, discovered that Tirzepatide significantly outperformed placebo in preventing diabetes, making it a breakthrough for those at risk. – This drug also showcased impressive weight loss effects in participants, shedding an average of 12.4% of their initial body weight, potentially aiding in the prevention of diabetes among high-risk individuals. – The results of this study suggest that Tirzepatide could be a game-changer in diabetes prevention and weight management for individuals in need of effective solutions. ### Hot Take: The findings on Tirzepatide’s ability to drastically lower diabetes risk and assist in weight loss are truly groundbreaking. If you are at high risk of diabetes or struggling with weight management, considering this medication could be a proactive step towards a healthier future. Contact Mindful Evolution today to explore how this innovative solution, along with our telehealth services, can support your journey to better health. **Weight Loss Disclaimer:** Individual results may vary. It’s essential to combine medication with a healthy diet and regular exercise for optimal weight loss and diabetes prevention outcomes. Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.